NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis reported today that its first-half 2016 revenues fell 7 percent year over year on lower collaboration revenues.

The firm reported total revenues of €6.1 million ($6.9 million) versus €6.6 million for the first half of 2015. Its product sales jumped 63 percent to €2.7 million from €1.7 million, due to a 314 percent year-over-jump increase in cartridge sales. Sales for its Idylla molecular diagnostics systems were down 21 percent to €988,000 from €1.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.